Introduction: The UK Renal Association Clinical Practice Guidelines include clinical performance measures for biochemical parameters in dialysis patients [1] . The UK Renal Registry (UKRR) annually audits dialysis centre performance against these measures as part of its role in promoting continuous quality improvement. Methods: Cross sectional performance analyses were undertaken to compare dialysis centre achievement of clinical audit measures for prevalent haemodialysis (HD) and peritoneal dialysis (PD) cohorts in 2007. The biochemical variables studied were phosphate, adjusted calcium, parathyroid hormone, bicarbonate and total cholesterol. In addition longitudinal analyses were performed (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007) to show changes in achievement of clinical performance measures over time. Results: Serum phosphate was between 1.1-1.8 mmol/L in 53% of HD and 64% of PD patients. Since 2003 there has been annual improvement in phosphate control for both HD and PD patients, largely through a reduction in phosphate >1.8 mmol/L. PD patients this year also showed a reduction in the percentage with a low phosphate. Adjusted calcium was between 2.2-2.6 mmol/L in 73% of HD and 78% of PD patients. Parathyroid hormone was between 16-32 pmol/L in 25% of HD and 27% of PD patients. The audit measure for bicarbonate was achieved in 71% of HD and 50% of PD patients. There was inter-centre variation for all variables studied. Conclusions: The UKRR consistently demonstrates inter-centre variation in achievement of biochemical clinical audit measures. Understanding the causes of this variation is an important part of improving the care of dialysis patients in the UK.
Introduction
The UKRR collected routine biochemical data from clinical information systems in renal centres in England, Wales and Northern Ireland. Annual cross sectional analyses were undertaken on some of these variables to determine centre level performance against national (Renal Association) clinical performance measures. This enabled UK renal centres to compare their own performance against each other and to the UK average performance [2] . The UK Renal Association Clinical Practice Guidelines were revised and the final version of the 4th edition of these guidelines was published in November 2007 (although a draft version was available for some time prior to this) [1] . Audit data for 2007 therefore spanned the adoption of these guidelines which included revision of some of the audit measures. Audit measures for kidney disease increasingly include tighter specification limits in conjunction with a growing evidence base. Out of range observations (e.g. hyperphosphataemia and hypophosphataemia) needed to be interpreted cautiously as they may relate to different clinical problems or population characteristics. These will therefore require different strategies to improve centre performance of clinical audit measures. The format of data presentation has been revised compared to previous UKRR reports [2] . To supplement these performance analyses, summary statistical data enhanced understanding of the population characteristics of each centre and longitudinal analyses demonstrated changes over time.
Methods
These analyses relate to biochemical variables in the prevalent dialysis cohort in England, Wales and Northern Ireland in 2007. The cohort studied were patients prevalent on dialysis treatment on 31/12/07. HD and PD cohorts were analysed separately.
The biochemical variables analysed were phosphate, calcium, parathyroid hormone, bicarbonate and cholesterol. The method of data collection and validation by the UKRR has been described elsewhere [3] . For each quarter of 2007 the UKRR extracted biochemical data electronically from clinical information systems in UK dialysis centres. The UKRR does not collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, a formula in widespread use was used to calculate adjusted calcium [2] . The audit measure for adjusted calcium in the 4th edition of the Renal Association Clinical Practice Guidelines depends on a local reference range [1] . To enable comparative audit the UKRR has continued to use adjusted calcium between 2.2-2.6 mmol/L as an audit measure. There are also a variety of methods and reference ranges in use to measure parathyroid hormone. To enable some form of comparative audit the UKRR has chosen 2-4 times the median upper laboratory value as the audit measure. This equates to 16-32 pmol/L and is comparable to KDOQI (15-31 pmol/L) [2, 4, 5] . The measure used for serum bicarbonate in the PD cohort was 25-29 mmol/L (the same as previous years) as the new audit measure specifies that serum bicarbonate should be maintained in the 'normal range'. A summary of the current Renal Association audit measures and conversion factors to SI units are given in table 10.1.
Quarterly values were extracted from the database for the last two quarters of 2007 for calcium, bicarbonate and phosphate, the last three quarters for iPTH and the entire year for cholesterol. Patients who did not have these data were excluded from the analyses. The completeness of data were analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots showing centre performance. Data were also excluded from plots when there were less than 20 patients with data at centre level. These data were analysed to calculate summary statistics (maximum, minimum, mean and median values in addition to standard deviation and quartile ranges). Where applicable, the percentage achieving the Renal Association or other surrogate clinical performance measure was also calculated. The number preceding the centre name in each figure indicates the percentage of missing data for that centre. Funnel plot analysis was used to identify 'outlying units' [6] . The percentage achieving each standard was plotted against centre size along with the upper and lower 95% and 99.9% limits. Centres can be identified on these plots by cross-referencing the 'n' value with the proportion of patients achieving the audit measure in the relevant table. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2000 to 2007. All data were unadjusted for case-mix.
Results

Mineral and bone parameters Phosphate
The 4th edition of the Renal Association Clinical Practice Guidelines states: 'Serum phosphate in dialysis patients (measured before a ''short gap'' dialysis session in HD patients) should be maintained between 1.1 and 1.8 mmol/L.' (Module 2: Complications) [1] The data for serum phosphate were 90% complete for HD patients and 95% complete for PD patients overall although there was considerable variation between centres. Data from HD patients in Coventry and London West and PD patients in London West were not included as there was a problem with data extraction (tables 10.2 and 10.4).
The individual centres' means and standard deviations are shown in tables 10.2 and 10.4.
There was between centre variation in the proportion of patients below, within and above the range specified by the clinical performance measure (figures 10.1-10.12). Fifty three percent (CI 53-54%) of HD patients and 64% (CI 62-66%) of PD patients achieved a phosphate between 1.1-1.8 mmol/L (tables 10.3 and 10.5). The proportion of HD patients with hyperphosphataemia was 31% (CI 31-32%) compared to 33% in 2006 and the proportion with hypophosphataemia was 15% (CI 15-16%) compared to 13% in 2006 (table 10.3 and figure 10.13). The proportion of PD patients with hyperphosphataemia was 26% (CI 24-27%) compared to 25% in 2006 and the proportion with hypophosphataemia was 10% (CI 9-11%) compared to 12% in 2006 (table 10.5 and figure 10.13).
Adjusted Calcium
The 4th edition of the Renal Association Clinical Practice Guidelines states: 'Serum calcium, adjusted for albumin concentration should be maintained within the normal reference range for the laboratory used (measured before a ''short gap'' dialysis session in HD patients) and ideally kept below 2.5 mmol/L.' (Module 2: Complications) [1] The audit measure for calcium in the 4th edition of the Renal Association clinical practice guidelines does not specify a lower limit for calcium and advises that adjusted calcium should be ideally within the normal range. For this reason the UKRR has continued to use 2.2-2.6 mmol/L as an audit measure for 2007 data. The guideline does however recommend that adjusted calcium should be <2.5 mmol/L. The UKRR is considering using 2.2-2.5 mmol/L as the audit measure for adjusted calcium in subsequent analyses. The data for adjusted calcium were 91% complete for HD patients and 96% complete for PD patients overall although there was between centre variation. Data from HD patients in London West were not included as there was a problem with data extraction As was the case for phosphate, there was between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure (figures 10.14-10.25). There was greater variation in the proportion of patients within range for adjusted calcium compared to phosphate most notably for HD patients. The funnel plot shows a greater number of centres outlying the 3SD limit i.e. there is over dispersion. 'The target range for parathyroid hormone measured using an intact PTH assay should be between 2 and 4 times the upper limit of normal for the intact PTH assay used. The same target range should apply when using the whole molecule PTH assay.' (Module 2: Complications) [1] The data for parathyroid hormone were 82% complete for HD patients and 84% complete for PD patients overall although there was between centre variation (tables 10.10 and 10.12). Twenty five percent (CI 24-26%) of HD patients and 27% (26-29%) of PD patients achieved a parathyroid hormone between 16-32 pmol/L (tables 10.11 and 10.13). The proportion of HD patients with a parathyroid hormone above the upper limit of the range was 40% (CI 40-41%) and the proportion with parathyroid hormone below the lower limit of the range was 35% (CI 34-36%) (table 10.11). The proportion of PD patients with parathyroid hormone above the upper limit of the range was 40% (CI 39-42%) and the proportion with parathyroid hormone below the lower limit of the range was 33% (CI 31-34%) (table 10.13). The proportion of dialysis patients achieving the Renal Association audit measure has reduced considerably with the introduction of a lower specification of the audit measure. Again there was between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure (figures 10 .27-10.38). Discussion -Mineral and bone parameters There were convincing observational data that hyperphosphataemia was associated with increased mortality in dialysis patients but the data linking calcium and parathyroid hormone to patient survival were less clear [7] [8] [9] [10] [11] . A recent cohort study has demonstrated that simultaneous achievement of all three audit measures does appear to be associated with better outcomes [12] .
The UKRR has consistently demonstrated between centre variation in achievement of audit measures for bone and mineral parameters but little is understood about the causes of this 'centre effect' . The complexity of the clinical processes required to manage mineral and bone disorders is probably further confounded by case mix. Finally it is important to consider data quality and the potential for measurement bias particularly in light of the variability in assay methods across the UK for calcium and parathyroid hormone. However, detecting these centre level differences is an important step in understanding the factors associated with exceptional performance.
Bicarbonate
The 4th edition of the Renal Association Clinical Practice Guidelines state:
'For HD patients pre-dialysis serum bicarbonate concentrations measured with minimum delay after venepuncture and before a 'short gap' dialysis session should be between 20 and 26 mmol/L (Module 3a: Haemodialysis)
For PD patients, Plasma bicarbonate should be maintained within the normal range.' (Module 3b: Peritoneal dialysis) [1] Results and discussion Bicarbonate data were 82% complete for HD patients and 81% complete for PD patients (tables 10.14 and 10.16). Seventy one percent (CI 70-72%) of HD patients and 50% (CI 49-52%) of PD patients achieved the audit measure for bicarbonate and there was inter-centre variation for both HD and PD (tables 10.15 and 10.17, figures 10.39 and 10.40). There was even greater between centre variation in the proportion of patients with bicarbonate values above and below the specified range for the audit measure (tables 10.15 and 10.17). The UKRR previously conducted a limited survey into the possible underlying causes of this variation. The study predominantly looked at measures of sample processing and of dialysis treatment. It did not adjust for case mix Blank cells denote centres excluded from analyses due to low patient numbers or poor data completeness n/a not applicable and was unable to detect any significant differences between centres. However, it was possible that there may be unmeasured processes including dialysis and oral bicarbonate prescription that might account for the variation observed [13] .
Total cholesterol
There is no audit standard for total cholesterol in the 4th edition of the Renal Association Clinical Practice Guidelines. Current guidance on lipid management states:
'Three hydroxy-3 methylglutaryl-Co-enzyme A reductase inhibitors (statins) should be considered for primary prevention in all CKD including dialysis patients with a 10-year risk of cardiovascular disease, calculated as >20% according to the Joint British Societies' Guidelines (JBS 2), despite the fact that these calculations have not been validated in patients with renal disease. The target total cholesterol should be <4 mmol/l or a 25% reduction from baseline, and a fasting low density lipoprotein (LDL)-cholesterol of <2 mmol/l or a 30% reduction from baseline, should be achieved, whichever is the greatest reduction in all patients (Evidence in CKD 1-3, Good Practice in CKD 4-5 and dialysis patients). Statins should not be withdrawn from patients in whom they were previously indicated and should continue to be prescribed when such patients start renal replacement therapy (RRT) or change modality. (Good Practice).' (Module 2: Complications) [1] Results and discussion Total cholesterol data were 80% complete for HD patients and 82% complete for PD patients. As there were no specific audit measures for total cholesterol, summary data were presented for each dialysis centre (tables 10.18 and 10.19, figures 10.41 and 10.42). There were a 
